Address for correspondence: Özlem Doğan MD, Department of Biochemistry, Medical School, Ankara University, Ankara, Turkey, phone: +90 532 711968, e-mail: ozlemceylandogan@gmail.com
Received: 26.02.2018, accepted: 20.03.2018.
Behçet’s syndrome and relationship with the ratio of insulin-like growth factor-1 (IGF-1)/IGF-binding protein-3 (IGFBP-3)
Özlem Doğan1, Emine Ünal2, Üçler Kısa3,Nurkan Aksoy4
1Department of Biochemistry, Medical School, Ankara University, Ankara, Turkey
2Department of Dermatology, Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Ankara, Turkey
3Department of Biochemistry, Medical School, Kırıkkale University, Kırıkkale, Turkey
4Department of Biochemistry, Yıldırım Beyazıt University, Yenimahalle Training and Research Hospital, Ankara, Turkey
Adv Dermatol Allergol 2019; XXXVI (3): 295–301 DOI: https://doi.org/10.5114/ada.2019.85640
A b s t r a c t
Introduction: Behçet’s syndrome (BS) is a chronic inflammatory disease with unknown aetiology. Insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) have important metabolic properties such as anabolic, cyto- protective and anti-inflammatory effects. Circulating IGF-1 and IGF-1/IGFBP-3 concentrations are associated with adiposity and insulin resistance.
Aim: To determine whether serum IGF-1 and IGFBP-3 levels or IGF-1/IGFBP-3 ratio were associated with the pres- ence or activity of BS.
Material and methods: Forty patients with BS (mean age: 39.6 ±10), and 20 healthy volunteers (mean age: 37 ±10.4) were enrolled. Serum IGF-1, IGFBP-3, and high sensitive C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) levels were measured in all subjects.
Results: Mean IGF-1 levels were low in both active BS and remission BS compared to the control group and mean IGF-1 levels were similar in active BS and remission BS. In active BS, mean IGFBP-3 levels were higher than in the control group and remission BS. There were positive correlations between these inflammatory cytokines and IGFBP-3 levels. IGF-1/IGFBP-3 ratio was lower in patients with BS compared to the healthy volunteer group, which was sta- tistically significant. IGF-1/IGFBP-3 ratio was lower in BS than in the control group independently of ESR and hs-CRP.
Conclusions: IGF-1 may play a diagnostic role to present itself in BS. IGF-1/IGFBP-3 ratio is not useful as an activation or remission criterion. The ratio may be a useful marker to predict the risk of BS presence in the critical population.
Key words: Behçet’s syndrome, insulin like growth factor-1, IGF-binding protein-3, inflammation.
Introduction
Behçet’s syndrome (BS) is associated with chronic immuno-inflammatory disease that affects several or- gans. The major clinical symptom is recurrent aphthous ulcer. There may be ocular inflammation, rheumatologic, gastrointestinal and skin involvement, and neurologi- cal symptoms and vascular complications may lead to a considerable level of morbidity. Its aetiology is not fully known yet. Pro-inflammatory cytokines such as interleu- kin (IL)-1, IL-6, IL-8, and tumor necrosis factor α (TNF-α) are elevated in BS patients and are closely associated with the clinical symptoms and disease activity in BS. Be- hçet’s syndrome has several clinical manifestations, may resemble the monogenic autoinflammatory disorders, and show abnormally increased inflammatory response.
Human leukocyte antigen (HLA)-B51 is the strongest sus-
ceptibility factor described so far which increases the dis- ease risk and typical phenotype [1–4]. Insulin resistance has been suggested as an etiological factor in BS [3, 5–7].
The insulin-like growth factors (IGFs) are natural pep- tides, which have similar structural homology with insulin.
IGFs circulate in plasma and form complexes into a family of structurally related binding proteins. These are called IGF-binding proteins (IGFBPs) [8]. IGF-1 is primarily syn- thesized in the liver and forms a primary response to GH.
Insulin-like growth factor binding protein-3 (IGFBP-3) is one of the six secretory glycoproteins of the IGFBP fam- ily. IGFBP-3 is a major regulator of IGF-1 and IGF-2 [9, 10].
IGFBP-1 and IGFBP-3 occur in all human body fluids, such as amniotic fluid, serum, placenta, endometrium, milk, urine, synovial fluid, interstitial fluid, and seminal fluid [8]. It is known that the differences in the IGF system are
indeed important in the regulation of glucose homeostasis [11, 12]. IGF-1 and its primary binding protein IGFBP-3 have important metabolic properties such as anabolic, cytopro- tective, and anti-inflammatory effects, and have a role in the apoptosis of many tumours [13–15]. IGF-1 is decreased in rheumatoid arthritis and juvenile idiopathic arthritis be- cause its synthesis is inhibited by inflammation [16]. IGFB- Ps may present biological functions with IGF-dependent and IGF-independent action. The underlying mechanisms mediating these biological actions of IGFBPs are largely unknown. IGFBPs may be mediated through cell surface receptors.
The molar IGF-1/IGFBP-3 ratio as an index for IGF-1 availability is used to investigate different conditions such as predicting the ovarian cancer risk, predicting the initiation of colorectal cancer, breast cancer risk, pro- viding additional non-invasive markers in HCV-related liver injury and insulin sensitivity in patients with type 2 diabetes, and cardiovascular events in recent studies [17–24]. IGFBP-3 may have therapeutic potential in RA [16]. It has been concluded that patients with BS exhibit peripheral insulin resistance; and this could be explained as diverse consequences of inflammation and endothe- lial dysfunction [6, 7, 25].
Aim
In the present study, we have investigated the role of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 ratio in BS.
Material and methods
Forty patients (20 active and 20 remission criteria), who were diagnosed with BS, according to Japanese crite- ria were enrolled in this study. The patients were recruited from the Yıldırım Beyazıt University Yenimahalle Training and Research Hospital. Smoking and alcohol consumption, chronic disease (primary/secondary hypertension, diabe- tes mellitus, coronary arterial disease, heart/liver/renal failure, B12 and folic acid deficiency), history of trauma in last 15 days, acute and chronic inflammatory disease, and drug abuse were considered as exclusion criteria.
Age and sex of the patients were recorded. Physical examination was performed and BS patients were divided into 2 subgroups of active and remission. Active or remis- sion criteria were used according to clinical criteria de- fined by Bayazıt et al. Active criteria were as follows: one or more oral aphthae presented in the last week, genital aphthae presented in the last 2 weeks, erythema nodo- sum like skin lesions presented in the last 2 weeks, and specific eye and organ involvement in the last week [1, 2].
Ethical status
The approval of the Yıldırım Beyazıt University ethics committee was obtained (2017-07-02).
Blood samples
Blood samples were collected and separated sera were stored in –80°C until processed.
Biochemistry analyses
IGF-1 DRG (DRG International Inc., USA) and IGFBP-3 DIAsource (DIAsource ImmunAssays S.A, Belgium) Elisa Kit, a solid phase enzyme-linked immunoabsorbent assay based on the principle of competitive binding, were used.
ESR levels were estimated using an automated method (Alifax, Padova, Italy).
Statistical analysis
Kolmogorov Smirnov test was used to determine, whether the distribution of continuous variables were nor- mal or not. Levene test was used for the evaluation of the homogeneity of variances. The continuous variables were shown as mean ± SD or median (25th–75th) percentiles, and the number of cases and percentages were used for cat- egorical data.
While the mean differences between the control and Behçet’s disease groups were compared by Student’s t test, Mann Whitney U test was applied for the compari- son of data with non-normal distribution. The comparison of more than two independent groups was analysed by one-way ANOVA or Kruskal Wallis test, where appropriate.
When the p-value from One-Way ANOVA or Kruskal Wallis test statistics were statistically significant, post-hoc Tukey HSD or Conover’s multiple comparison test were used to de- termine which group was different from others. Categorical data were evaluated by Pearson’s c2 or continuity corrected c2 test, where applicable. Degrees of association between continuous variables were evaluated by Spearman’s Rank Correlation analyses.
The continuity of the differences in laboratory mea- surements (i.e. IGFBP-3, IGF-1 and IGF-1/IGFBP-3) between control and patient groups was evaluated by multiple lin- ear regression analyses after adjusting for all possible con- founding factors. Any variable with a p-value of < 0.10 in univariable test was accepted as a candidate for the multi- variable model along with all variables with known clinical importance. Coefficient of regression and 95% confidence interval for each independent variable were also calculated.
Data analysis was performed by using IBM SPSS Sta- tistics version 17.0 software (IBM Corporation, Armonk, NY, USA). P-value of less than 0.05 was considered statistically significant.
Results
There were no differences between the control and BS groups as to mean age and gender distribution (p = 0.347 and p = 1.000, respectively). The mean body mass index (BMI) levels were also similar between the two groups (p = 0.249). Half of the patients had active dis-
ease and the other half were in remission. There were no statistical differences between the control group, active BS and remission BS according to average age, gender, and BMI, respectively (p = 0.642, p = 0.932, p = 0.313).
These results are summarized in Table 1.
Results of blood levels belonging to active and remis- sion Behçet’s groups and comparison with the control group are shown in Table 1.
There were no statistical differences between active and remission BS as to mean disease duration, lipid pro- files, active organ involvement, and administration of therapy (p > 0.05). In the Behçet’s group, the erythrocyte sedimentation rate (ESR) and high sensitive C-reactive protein (hs-CRP) levels were statistically higher compared to the control group (p < 0.001).
The ESR levels were statistically higher in active and remission Behçet’s groups compared to the control group (p = 0.004 and p < 0.001). The ESR levels were statistically higher in active Behçet’s group compared to the remission Behçet’s group (p < 0.001). Hs-CRP levels were higher in the active Behçet’s group and the remission Behçet’s group compared to the control group (p < 0.001 and p < 0.001, re- spectively). Hs-CRP levels were higher in the active Behçet’s group than the remission Behçet’s group (p < 0.001). The levels of mean IGFBP3 were higher in BS than in the control group, and mean IGF-1 and molar IGF-1/IGFBP3 ratio was lower in BS in a statistically significant manner compared to the control group (p < 0.001).
In Figure 1, IGF-1 and IGFBP-3 levels in control and active- remission BS groups are given.
IGF-1 levels
Mean IGF-1 levels were low in both active BS (p <
0.001) and remission BS (p = 0.030), compared to the
control group (Figure 1) and mean IGF-1 levels were simi- lar between active BS and remission BS (p = 0.467).
IGF-1 levels were lower than the healthy controls both in the active BS (B = –168.546, 95% CI: –300.120 – –36.972 and p = 0.013) and the remissions BS (B = –107.475, 95% CI: –192.580 – –22.370 and p = 0.014) that IGF-1 level was an independent factor in BS of both ESR and hs-CRP (B = –108.98, 95% CI: –193.508 – –22.687 and p = 0.014) (Tables 2, 3).
IGFBP-3 levels
The levels of mean IGFBP3 were not statistically different between the control group and the remission group of BS (p = 0.453). In active BS, mean IGFBP-3 levels
Table 1. Clinic (ESR, hs-CRP, IGF-1, IGFBP-3, IGF-1/IGFBP-3 values for all groups) and demographic values of all groups Parameter Controls (n = 20) Patients (n = 40) P-valuea Remission (n = 20) Active (n = 20) P-valueb
Age [years] 37.0 ±10.4 39.6 ±10.0 0.347 39.4 ±10.0 39.8 ±10.2 0.642
Female gender 12 (60.0%) 25 (62.5%) 1.000 13 (65.0%) 12 (60.0%) 0.932
BMI [kg/m2] 25.8 ±3.7 27.1 ±4.2 0.249 26.5 ±4.2 27.8 ±4.3 0.313
Duration of disease [months]
– 60.0 (36.0–148.5) – 84.0 (37.0–192.0) 54.0 (18.7–114.0) 0.114
Organ involvement – 25 (62.5%) – 10 (50.0%) 15 (75.0%) 0.191
Treatment receiving – 30 (75.0%) – 13 (65.0%) 17 (85.0%) 0.273
ESR 7.6 ±5.3A,B 24.0 ±11.4 < 0.001 15.3 ±8.7A,C 30.7 ±9.7B,C < 0.001
Hs-CRP 0.83 ±0.34A,B 3.66 ±1.3 < 0.001 3.32 ±1.1A,C 5.77 ± 1.2B,C < 0.001 IGFBP-3 2427.4 ±431.1B 3044.1 ±961.4 < 0.001 2729.4 ±513.0C 3358.9 ±1193.9B,C 0.002 IGF-1 404.0 ±106.3A,B 285.3 ±122.3 < 0.001 307.2 ±109.8A 263.4 ±132.8B < 0.001 IGF-1/IGFBP-3 0.17 ±0.063A,B 0.10 ±0.046 < 0.001 0.12 ±0.041A 0.08 ±0.047B < 0.001
aThe comparison between the control and patient group, bthe comparison among the control, remission and active disease groups. AControl vs. remission (p < 0.05), Bcontrol vs. active (p < 0.001), Cremission vs. active (p < 0.05). ESR – erythrocyte sedimentation rate, hs-CRP – high sensitive C-reactive protein, IGFBP-3 – insulin-like growth factor binding protein-3, IGF-1 – insulin-like growth factor-1, IGF-1/IGFBP-3 – insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio.
Level
4000 3500 3000 2500 2000 1500 1000 500
0- IGF-1 IGFBP-3
Figure 1. IGF-1 and IGFBP-3 levels in control, active and re- mission groups
*p < 0.05 Control group levels higher than remission and active BS,
•p < 0.001 Active BS levels higher than remission BS and control group.
Control Remission Active
were statistically higher than in the control group and the remission BS (p < 0.001 and p = 0.038, respectively) (Figure 1). There was a statistical and positive correla- tion between levels of ESR and IGFBP-3 (r = 0.440 and p < 0.001) and there were similar correlations between Table 2. IGF-1, IGFBP-3 and IGF-1/IGFBP-3 levels and correlation with other factors (remission Behçet, active Behçet, ESR, hs-CRP)
Parameter Coefficient of regression
95% Confidence interval
P-value
IGF-1:
Remission –107.47 –192.58 – –22.37 0.014 Active –168.54 –300.12 – –36.97 0.013
ESR 0.23 –3.71 – 4.18 0.906
Hs-CRP 4.66 –10.82 – 20.14 0.549
IGFBP-3:
Remission 138.93 –437.77 – 715.65 0.631
Active 549.79 –339.9 – 1439.4 0.221
ESR 7.68 –18.86 – 34.24 0.564
Hs-CRP 30.25 –73.81 – 134.31 0.562
IGF-1/IGFBP-3:
Remission –0.056 –0.094 – –0.018 0.004
Active –0.086 –0.144 – –0.028 0.005
ESR –0.0002 –0.002 – 0.002 0.846
Hs-CRP 0.001 –0.006 – 0.008 0.836
ESR – erythrocyte sedimentation rate, hs-CRP – high sensitive C-reactive pro- tein, IGFBP-3 – insulin-like growth factor binding protein-3, IGF-1 – insulin- like growth factor-1, IGF-1/IGFBP-3 – insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio.
Table 3. The effect of Behçet’s syndrome on IGF-1, IGFBP-3, and IGF-1/IGFBP-3 levels according to multivariate analyses
Parameter Coefficient of regression
95% Confidence interval
P-value
IGF-1:
Behçet’s –108.09 –193.50 – –22.68 0.014
ESR –0.97 –4.39 – 2.44 0.570
Hs-CRP 1.59 –13.07 – 16.27 0.828
IGFBP-3:
Behçet’s 141.59 –437.26 – 720.44 0.626
ESR 15.79 –7.17 – 38.77 0.174
Hs-CRP 50.84 –47.81 – 149.50 0.306
IGF-1/IGFBP-3:
Behçet’s –0.056 –0.094 – –0.018 0.004
ESR –0.001 –0.002 – 0.001 0.319
Hs-CRP –0.001 –0.007 –– 0.006 0.810
ESR – erythrocyte sedimentation rate, hs-CRP – high sensitive C-reactive pro- tein, IGFBP-3 – insulin-like growth factor binding protein-3, IGF-1 – insulin- like growth factor-1, IGF-1/IGFBP-3 – insulin-like growth factor-1/insulin-like growth fa ctor binding protein-3 ratio.
Table 4. IGF-1, IGFBP-3 and IGF-1/IGFBP-3 levels and correlation factors with age, BMI, ESR, hs-CRP
Parameter IGF-1 IGFBP-3 IGF-1/IGFBP-3
Age:
Coefficient of correlation –0.07 0.03 –0.09
P-value 0.59 0.80 0.48
BMI:
Coefficient of correlation –0.001 0.005 –0.01
P-value 0.99 0.97 0.94
ESR:
Coefficient of correlation –0.29 0.44 –0.43 P-value 0.024 < 0.001 < 0.001 Hs-CRP:
Coefficient of correlation –0.23 0.43 –0.39
P-value 0.07 < 0.001 0.002
IGF-1 – insulin-like growth factor-1, IGFBP-3 – insulin-like growth factor bind- ing protein-3, IGF-1/IGFBP-3 – insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio, BMI – body mass index, ESR – erythrocyte sedi- mentation rate, hs-CRP – high sensitive C-reactive protein.
the hs-CRP levels and IGFBP-3 levels (r = 0.430 and p < 0.001) (Table 4).
IGFBP-3 levels were not a useful marker for predicting the activation and remission of BS according to multiple linear regression analyses after being adjusted for all possible confounding factors (p = 0.631 and p = 0.221).
IGF-1/IGFBP-3 ratio
According to the control group, mean IGF-1/IGFBP-3 levels were lower in the active BS (p < 0.001) and the remission BS (p = 0.002), and mean IGF-1/IGFBP-3 levels were similar between the active BS and the remission BS (p = 0.146).
IGF-1/IGFBP-3 ratio was a predictive factor for BS and it was an independent factor in BS both in inactive (B = –0.056, 95% CI: –0.094 – –0.018 and p = 0.004) and active patients (B = –0.086, 95% CI: –0.144 – –0.028 and p = 0.005). IGF-1/IGFBP-3 ratio was lower in BS than in the control group and it was an independent factor with respect to ESR and hs-CRP (B = –0.056, 95% CI: –0.094 – –0.018 and p = 0.004) (Table 3).
There were no differences with regard to sex, BS treatment, and systemic organ involvement in the levels of IGFBP3 and IGF-1, and IGF-1/IGFBP-3 ratio (p > 0.05) as shown in Table 5.
Discussion
Behçet’s syndrome is a chronic recurrent systemic in- flammatory disease. The symptoms are observed concur- rently or in different time periods. The site and timing of activation periods could not be predicted. Behçet’s syn-
drome is characterized by recurrent attacks affecting the mucocutaneous tissues, eyes, joints, blood vessels, brain, and gastrointestinal tract. It is a multifactorial disease that affects variable vessel vasculitis.
Metabolic syndrome (MetS) is characterized by cen- tral obesity, elevated triglycerides (TG), reduced high- density lipoproteins (HDL), impaired fasting blood glu- cose (FBG), and hypertension. Yalçın et al. suggested that all BS patients should be closely monitored for hyper- tension, hyperlipidaemia, and diabetes mellitus to avoid MetS development [25]. It has been concluded that pa- tients with BS exhibit peripheral insulin resistance; and this could be explained as the diverse consequences of inflammation and endothelial dysfunction.
Insulin-like growth factor-1 is the major member of the insulin-like growth factor family and it is considered to exert anabolic effects and to mediate the proliferation of multiple tissues. Hepatocytes are the major source of circulating IGF-1 [26–29]. IGF-1 can be produced locally by many types of peripheral cells under basal conditions, as well as in response to inflammation. In this case, IGF-1 acts as an autocrine or a paracrine factor like many cyto- kines and growth factors. The IGFBPs transport IGF-1 in the bloodstream and exhibit unique biological actions, including cell growth inhibition or promotion and induc- tion of apoptosis. IGFBP-3 is the most abundant form, with the highest affinity for IGF-1. Less than 1% of IGF-1 circulates in free form in the bloodstream. Low IGF-1 lev- els were observed in chronic diseases and malnutrition while IGFBP-3 remained relatively unchanged [13–15, 27].
In the present study, mean IGF-1 levels were lower in the active BS (p < 0.001) and the remission BS (p = 0.030) compared to the healthy control group. This may be due to the increase in IGFBP-3 levels in BS. The reason of this is that a high level of IGFBP-3 reduces IGF-1 action, while decreasing free IGF-1 level, as it is known.
IGFBP-3 is also produced by peripheral tissues and can be upregulated by a variety of molecules, such as GH, IL-1, TNF-α, transforming growth factor-β1, gluco- corticosteroids, retinoic acid, vitamin D, antioestrogens, and antiandrogens [30, 31]. The levels of circulating IGF-1 and IGFBP-3 are affected by several factors, such as age, hormones, nutrition, and comorbidities [15]. In the pres- ent study, mean age and demographical features were also similar in each group. Some authors have suggested that inflammatory markers and IGF-1 and IGFBP-3 levels differ in obesity [28, 29]. In our study, BMI levels were similar between the groups and did not have an effect on the IGF-1 levels and IGF-1/IGFBP-3 ratio (p > 0.05). The conclusion was that the presence of large amounts of IGFBP-3 caused a reduction in the free IGF levels, while small amounts of IGFBP-3 protected IGFs, intensifying their effects.
Systemic inflammation was marked by higher levels of hs-CRP and both higher levels of GH and lower lev- els of IGF-1 and IGFBP-3. In turn, higher GH and lower
IGFBP-3 levels were associated with a shorter stature.
These findings are consistent with a model of inflamma- tion driving hepatic resistance to GH signalling as noted in preclinical studies. Similarly, reduction in serum IGF-1 by dietary restriction in animal models slows tumour progression and increases apoptosis in tumour cell ef- fects that are both reversed by infusions of recombinant IGF-1 [15].
IGF-1 levels were lower in BS and it was an indepen- dent factor of ESR and hs-CRP (a diagnostic predictive factor) (B = –108.098, 95% CI: –193.508 – –22.687 and p = 0.014).
There was an increase in inflammatory markers such as ESR and hs-CRP in both the active and the remission patients. In active patients, these levels were also higher than in the remission patients as expected. There was a positive correlation between these inflammatory cy- tokines and IGFBP-3 levels, respectively (ESR r = 0.44, p < 0.001), and hs-CRP (r = 0.43 and p < 0.001). There was a statistically significant negative correlation be- tween IGF-1 and ESR (r = –0.291 and p = 0.024) and there was no statistically significant correlation between IGF-1 and hs-CRP (p > 0.05). During the regression analy- ses, it was found that the levels of IGF-1 were lower in BS and independent of ESR and hs-CRP (B = –108.098, 95% CI: –193.508 – –22.687 and p = 0.014). The reason may be that the levels of ESR and hs-CRP increase in BS, and these inflammatory markers directly induce (not affect IGF-1) the production of IGFBP-3. Subsequently, IGFBP-3 binds to the free IGF-1 and the level of IGF-1 de- creases in the bloodstream. Another mechanism may be due to insulin resistance in BS. IGFBP-3 may be mediated by an unknown trigger through impaired cell surface re- Table 5. IGF-1, IGFBP-3 and IGF-1/IGFBP-3 levels according to gender, organ involment and treatment receiving
Parameter N IGF-1 IGFBP-3 IGF-1/IGFBP-3 Gender:
Female 37 318.2 ±137.4 2973.1 ±983.0 0.12 ±0.064 Male 23 335.6 ±117.2 2622.1 ±607.3 0.14 ±0.059
P-value 0.616 0.130 0.246
Organ involvement:
No 15 273.7 ±110.9 2725.7 ±555.2 0.11 ±0.044 Yes 25 292.3 ±130.4 3235.2 ±1104.8 0.10 ±0.048
P-value 0.648 0.105 0.619
Treatment receiving:
No 10 272.4 ±123.4 2779.8 ±602.8 0.10 ±0.044 Yes 30 289.6 ±123.8 3132.3 ±1047.8 0.10 ±0.048
P-value 0.705 0.322 0.965
ESR – erythrocyte sedimentation rate, hs-CRP – high sensitive C-reactive pro- tein, IGFBP-3 – insulin-like growth factor binding protein-3, IGF-1 – insulin- like growth factor-1, IGF-1/IGFBP-3 – insulin-like growth factor-1/insulin-like growth factor binding protein-3 ratio.
ceptors in BS. Insulin also up-regulates IGFBP-3 levels, as known. Otherwise, it may be an unknown immunological mechanism.
In active BS, mean IGFBP-3 levels were statistically higher than in the control group and the remission BS (p < 0.001 and p = 0.038, respectively). The levels of mean IGFBP-3 were not statistically different (were similar) between the control group and the remission group of BS (p = 0.453). In the active BS, inflammatory markers such as IL-1, TNF-α, TGF-β1 were increased, as known, and this inflammatory response might induce the production of IGFBP-3 and its subsequent increase.
Therefore, the levels of IGF-1 may decrease in the blood- stream. Nevertheless, during the regression analyses, the effects of IGFBP-3 were not statistically different in the active (p = 0.221) and the remission BS (p = 0.631).
IGF-1 levels were lower than in the healthy controls and IGF-1 level was an independent factor in BS for both ESR and hs-CRP, both in the active BS (B = –168.546, 95% CI: –300.120 – –36.972 and p = 0.013) and the remis- sion BS (B = –107.475, 95% CI: –192.580 – –22.370 and p = 0.014) according to multiple linear regression analy- ses after being adjusted for all possible confounding fac- tors. It may be due to inflammation in BS and possible insulin resistance that up-regulates the production of IGF-1 and IGFBP-3; furthermore, IGFBP-3 transports IGF-1 to tissues and causes organ inflammation.
These findings suggest that reduced levels of IGF-1 in circulation and increased blood levels of IGFBP-3 in BS may result in suppression of its anti-inflammatory func- tions, and therefore IGF-1 may play a diagnostic role to present itself.
The IGF-1/IGFBP-3 ratio was lower in BS in a statis- tically significant manner as compared to the healthy control group, and the ratio was independent of ESR and hs-CRP.
Conclusions
We have found that the IGF-1/IGFBP-3 ratio was lower in BS and it was an independent factor of ESR and hs- CRP according to multivariate regression analyses. The IGF-1/IGFBP-3 ratio may be a useful parameter for pre- dicting the presence of BS; however, further studies are required on this subject.
Conflict of interest
The authors declare no conflict of interest.
References
1. Behçet H. Uber rezidivierende Aphthöse, durch ein Virus verusachte Geschwüre am Mund, am Auge und an den Genitale. Dermatol Wochenschr 1937; 105: 1152.
2. Bayazit N, Yılmaz M, Oral B, et al. Immunologic activation parameters in Behcet’s disease. Turk J Dermatol 2008; 2:
34-8.
3. Oguz A, Dogan EG, Uzunlulu M, Oguz FM. Insulin resistance and adiponectin levels in Behcet’s syndrome. Clin Exp Rheu- matol 2007; 25 (4 Suppl 45): S118-9.
4. Alan S, Tuna S, Turkoglu EB. The relation of neutrophil-to- lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume with the presence and severity of Behcet’s syndrome. Kaohsiung J Med Sci 2015; 31: 626-31.
5. Sahin E, Karaman G, Uslu M, et al. Adiponectin levels, in- sulin resistance and their relationship with serum levels of inflammatory cytokines in patients with Behcet’s disease.
J Eur Acad Dermatol Venereol 2012; 26: 1498-502.
6. Erdem H, Dinc A, Pay S, et al. Peripheral insulin resistance in patients with Behcet’s disease. J Eur Acad Dermatol Vene- reol 2006; 20: 391-5.
7. Kim SK, Choe JY, Park SH, et al. Increased insulin resistance and serum resistin in Korean patients with Behcet’s disease.
Arch Med Res 2010; 41: 269-74.
8. Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor- binding proteins in serum and other biological fluids: regula- tion and functions. Endocr Rev 1997; 18: 801-31.
9. Bonefeld K, Moller S. Insulin-like growth factor-I and the liver. Liver Int 2011; 31: 911-9.
10. Mallea-Gil MS, Ballarino MC, Spiraquis A, et al. IGF-1 levels in different stages of liver steatosis and its association with metabolic syndrome. Acta Gastroenterol Latinoam 2012; 42:
20-6.
11. Garten A, Schuster S, Kiess W. The insulin-like growth fac- tors in adipogenesis and obesity. Endocrinol Metab Clin North Am 2012; 41: 283-95, v-vi.
12. Cheng CW, Yilmaz OH. IGFBP3 and T1D: systemic factors in colonic stem cell function and diabetic enteropathy. Cell Stem Cell 2015; 17: 379-80.
13. Castilla-Cortazar I, Guerra L, Puche JE, et al. An experimen- tal model of partial insulin-like growth factor-1 deficiency in mice. J Physiol Biochem 2014; 70: 129-39.
14. Genre F, Lopez-Mejias R, Rueda-Gotor J, et al. IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylos- ing spondylitis patients undergoing anti-TNF-alpha therapy.
BioMed Res Int 2014; 2014: 671061.
15. Lee HS, Woo SJ, Koh HW, et al. Regulation of apoptosis and inflammatory responses by insulin-like growth factor bind- ing protein 3 in fibroblast-like synoviocytes and experimen- tal animal models of rheumatoid arthritis. Arthritis Rheuma- tol 2014; 66: 863-73.
16. Sarzi-Puttini P, Atzeni F, Scholmerich J, et al. Anti-TNF anti- body therapy improves glucocorticoid-induced insulin-like growth factor-1 (IGF-1) resistance without influencing myo- globin and IGF-1 binding proteins 1 and 3. Ann Rheum Dis 2006; 65: 301-5.
17. Koegelenberg AS, Schutte R, Smith W, Schutte AE. Bioavail- able IGF-1 and its relationship with endothelial damage in a bi-ethnic population: the SABPA study. Thromb Res 2015;
136: 1007-12.
18. Wang Q, Bian CE, Peng H, et al. Association of circulating insulin-like growth factor 1 and insulin-like growth factor binding protein 3 with the risk of ovarian cancer: a system- atic review and meta-analysis. Mol Clin Oncol 2015; 3: 623-8.
19. Mohajeri Tehrani MR, Tajvidi M, Kahrizi S, Hedayati M. Does endurance training affect IGF-1/IGFBP-3 and insulin sensi- tivity in patients with type 2 diabetes? J Sports Med Phys Fitness 2015; 55: 1004-12.
20. Jiang B, Zhang X, Du LL, et al. Possible roles of insulin, IGF-1 and IGFBPs in initiation and progression of colorectal cancer.
World J Gastroenterol 2014; 20: 1608-13.
21. Adamek A, Kasprzak A, Mikos H, et al. The insulin-like growth factor-1 and expression of its binding protein 3 in chronic hepatitis C and hepatocellular carcinoma. Oncol Rep 2013; 30: 1337-45.
22. Meggiorini ML, Cipolla V, Borgoni G, et al. Possible effects of insulin-like growth factor-I, IGF-binding protein-3 and IGF-1 /IGFBP-3 molar ratio on mammographic density: a cross- sectional study. Eur J Gynaecol Oncol 2012; 33: 74-8.
23. Yoon YS, Keum N, Zhang X, et al. Circulating levels of IGF-1, IGFBP-3, and IGF-1/IGFBP-3 molar ratio and colorectal adeno- mas: a meta-analysis. Cancer Epidemiol 2015; 39: 1026-35.
24. Kong AP, Choi KC, Wong GW, et al. Serum concentrations of insulin-like growth factor-I, insulin-like growth factor binding protein-3 and cardiovascular risk factors in adolescents. Ann Clin Biochem 2011; 48: 263-9.
25. Yalcin B, Gur G, Artuz F, Alli N. Prevalence of metabolic syn- drome in Behcet disease: a case-control study in Turkey. Am J Clin Dermatol 2013; 14: 421-5.
26. Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res 2003; 13: 113-70.
27. Mohanraj L, Kim HS, Li W, et al. IGFBP-3 inhibits cytokine- induced insulin resistance and early manifestations of ath- erosclerosis. PLoS One 2013; 8: e55084.
28. Ben Ounis O, Elloumi M, Zouhal H, et al. Effect of individual- ized exercise training combined with diet restriction inflam- matory markers and IGF-1/IGFBP-3 in obese children. Ann Nutr Metab 2010; 56: 260-6.
29. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Po- tischman N. Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels by race/ethnicity and gender. Ann Epidemiol 2009; 19: 841-9.
30. Underwood LE, Thissen JP, Lemozy S, et al. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res 1994; 42: 145-51.
31. Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J Clin Endocrinol Metab 1995; 80: 443-9.
